nach oben

Erschienen in:

01.06.2019 | Case report

Rifampicin/sitafloxacin

Various toxicities: 5 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

In a retrospective study of 31 patients treated with sitafloxacin-containing regimen between January 2010 and July 2017 at Keio University Hospital, 5 patients [ages and sexes not stated] were described, of whom one patient developed liver dysfunction following treatment with rifampicin, whereas 4 patients developed rash (2 patients), haemoptysis (1 patient) and gastrointestinal disturbance (1 patient) during treatment with sitafloxacin for Mycobacterium avium complex associated lung disease (MAC-LD). …

Asakura T, et al. Sitafloxacin-containing regimen for the treatment of refractory mycobacterium avium complex lung disease. Open Forum Infectious Diseases 6: ofz108, No. 4, Apr 2019. Available from: URL: http://doi.org/10.1093/ofid/ofz108 - Japan

Titel: Rifampicin/sitafloxacin
Various toxicities: 5 case reports
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-64121-0

Springer Medizin

Rifampicin/sitafloxacin

Various toxicities: 5 case reports

Excerpt

Weitere Artikel der Ausgabe 1/2019

Docetaxel

Warfarin

Bortezomib/carfilzomib/dexamethasone

Etidronic-acid

Epirubicin/trastuzumab

BCG

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Docetaxel

Warfarin

Bortezomib/carfilzomib/dexamethasone

Etidronic-acid

Epirubicin/trastuzumab

BCG